FDA sends warning letters to four research-peptide sellers over semaglutide and retatrutide products
DOCUMENTED. FDA posted warning letters on Dec. 17, 2024 (dated Dec. 10) to four online sellers of research peptides, saying their semaglutide, retatrutide and related products are unapproved new drugs. The letters are FDA’s allegations; each firm had 15 working days to respond.
Attribution: Compiled from the four warning letters as posted on FDA’s website, read on October 5, 2026. We have not seen any company response. This is an archive entry added after publication of the later 2026 letters.
Allegations in government documents and in reports by others are theirs, not findings by us. Verify against the linked sources. Disclaimer.
By Peptide Industry Gossip · Observed · Published
What happened
- On Dec. 17, 2024, FDA posted four warning letters dated Dec. 10, 2024 to sellers marketing peptide products online.
- The recipients are Prime Vitality, Inc. dba Prime Peptides (Santa Barbara, CA), Swisschems (New York, NY), Xcel Research LLC (Sheridan, WY) and Summit Research Peptides (Hoover, AL), per the addresses in the letters.
- Products named across the letters include semaglutide, retatrutide, tirzepatide, cagrilintide and mazdutide; the Xcel letter also names survodutide and sermorelin. All four letters quote research-only wording from the firms’ labeling or sites, such as “research use only” or “research chemicals only.”
- Each letter gave the firm 15 working days from receipt to describe the steps it had taken to correct the violations.
What we can verify
- FDA posted all four letters on Dec. 17, 2024; they remained on FDA’s site when we read them on Oct. 5, 2026.
- Each letter cites sections 505(a) and 301(d) of the FD&C Act and the 15-working-day response window.
What remains unknown
- Whether any of the four responded, removed the listed products, or faced further action.
- Whether the four sites are still operating; we did not check them.
Timeline
| Date / time | Event |
|---|---|
| 2024-12-10 | Date on all four letters: Prime Peptides, Swisschems, Xcel Research and Summit Research Peptides. |
| 2024-12-17 | FDA posts the four letters. Each gives the firm 15 working days from receipt to respond. |
| 2025-12-23 | FDA posts a later warning letter to Pinnacle Professional Research dba Pinnacle Peptides, which names SARMs products. |
| 2026-04-07 | FDA posts five more peptide-seller letters (dated Mar. 31, 2026). |
| 2026-09-01 | FDA posts five further letters (dated Aug. 24, 2026) rejecting “research use only” labeling. |
Receipts
- FDA warning letter: Prime Vitality, Inc. dba Prime Peptides (Dec. 10, 2024) · captured 2026-10-05 · tier 1
- FDA warning letter: Swisschems (Dec. 10, 2024) · captured 2026-10-05 · tier 1
- FDA warning letter: Xcel Research LLC (Dec. 10, 2024) · captured 2026-10-05 · tier 1
- FDA warning letter: Summit Research Peptides (Dec. 10, 2024) · captured 2026-10-05 · tier 1
- FDA warning letters table (searched for “peptide” on Oct. 5, 2026) · captured 2026-10-05 · tier 1
- Frier Levitt: Peptides Under the Microscope (Jan. 29, 2026), which notes FDA letters to online peptide sellers in late 2024 · captured 2026-10-05 · tier 2
Company response
No company response located as of the publish date.
Why people care
This is one of the first groups of letters in a run that continued through December 2025, March 2026, June 2026 and August 2026. The sellers named here marketed the same GLP-1-class products that dominate the later letters.
Corrections and update log
No corrections or updates. Request a correction.
Related vendor records
Related stories
DOCUMENTED. FDA posted warning letters on Sept. 1, 2026 (dated Aug. 24) to five peptide sellers, stating that products sold as “research use only” are unapproved new drugs. The letters are FDA’s allegations; each firm was told to respond within 15 business days.
REPORTED. FDA’s page confirms a July 23-24, 2026 advisory committee meeting on seven peptides; outlets report the panel supported six of them (including BPC-157) for the 503A bulks list and rejected one. The votes are nonbinding and a formal rule would be needed before pharmacies could compound them.
DOCUMENTED. FDA posted warning letters on Apr. 7, 2026 (dated Mar. 31) to five peptide sellers, citing unapproved new drug violations; all five letters also name bacteriostatic water sold alongside the peptides. The letters are FDA’s allegations; each firm had 15 working days to respond.